
    
      The primary objective of this pivotal study is to investigate the safety and efficacy of
      fidaxomicin versus vancomycin in subjects with Clostridium difficile-associated diarrhea
      (CDAD). The cure rates at end of therapy and recurrence rates will be evaluated and compared.
    
  